Dr Nassir Marrouche (Executive Director, CARMA Center, University of Utah, Salt Lake City, UT, USA) spoke to us at Heart Rhythm 2019 on the ablation outcomes from the Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE AF) trial, along with the current unmet needs in catheter ablation and his highlights from the meeting.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Nassir Marrouche has received consultancy fees from Abbott, Biosense Webster, Biotronic, Boston Scientific, Marrek Inc., Medtronic, Preventice and Vytronus, and received research grants from Abbott, Biosense Webster, Biotronic, Boston Scientific, GE Healthcare, Siemens and Vytronus. He has company interest in Marrek Inc. and Cardiac Design.
1. What were the key findings of the Catheter Ablation vs. Standard Conventional Treatment in Patients with LV Dysfunction and AF (CASTLE-AF) trial? (0:06)
2. How should the benefits shown in CASTLE-AF, including mortality reduction and quality of life improvement, influence patient management and current practice in atrial fibrillation and heart failure? (1:08)
3. What are your highlights from Heart Rhythm 2019? (2:16)
4. What are the current unmet needs in catheter ablation? (3:34)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Atrial Fibrillation
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!